News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Ad's Legal Fight Ends

February 1, 2002
By Jill Wechsler, Pharm Exec’s Washington Correspondent
Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-02-01-2002

Washington, DC-Pro-life advocates recently dropped a lawsuit challenging the promotion of abortifacient RU-486 through ads sponsored by the National Abortion Federation. The suit charged NAF with using deceptive advertising by promoting Mifepristone as safe in several national magazines, including Self, Cosmopolitan, InStyle, Vanity Fair, and People. The ads stated, "You have the freedom to choose. And now, you have another safe abortion choice."

Washington, DC-Pro-life advocates recently dropped a lawsuit challenging the promotion of abortifacient RU-486 through ads sponsored by the National Abortion Federation. The suit charged NAF with using deceptive advertising by promoting Mifepristone as safe in several national magazines, including Self, Cosmopolitan, InStyle, Vanity Fair, and People. The ads stated, "You have the freedom to choose. And now, you have another safe abortion choice."

The suit filed in Chicago circuit court last August claimed the ads should describe side effects from the abortion pill, as required by Illinois law. The plaintiffs backed out in January, saying that only state attorneys general or the Federal Trade Commission had the resources to carry on the fight. They also cited personal plans to be involved in political races in Illinois in coming months.

NAF executive director Vicki Saporta claimed victory against "this frivolous lawsuit" and says the withdrawal indicates it "had absolutely no merit." She says the plaintiffs brought the case "solely to advance their antichoice agenda" and that NAF's public education campaign provides accurate information about the product. Many clinics and doctors have been reluctant to prescribe Mifepristone for fear of lawsuits or protests, and the NAF campaign was an effort to build consumer demand.

Articles in this issue

Consumer Communication in Europe Stalls
Infinity from Zero
Striking the Right Balance
Striking the Right Balance
Pfizer on the Front Lines
Pfizer on the Front Lines
chart1-9164-1408722345396.jpg
Ad's Legal Fight Ends
Top 10 Detailing Pitfalls
Top 10 Detailing Pitfalls
Abbott and Bayer Take Another PR Hit
CRM Checklist for Success
CRM Checklist for Success
Poor Health and Poverty Are Linked
Spending Debate Heats Up
HHS Advisory Panel to Push Regulatory Reforms
Running a Tight Ship
Running a Tight Ship
Recent Videos
Related Content

Bridging the Gap:  A Large Pharma Blueprint

Bridging the Gap: A Large Pharma Blueprint

David Kamenir
May 9th 2025
Article

Five steps for organizations in bringing enterprise-level strategies to life.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Sujay Jadhav

How External Control Arms are Improving Clinical Trials: Q&A with Sujay Jadhav

Mike Hollan
May 9th 2025
Article

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy

Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy

Don Tracy, Associate Editor
May 9th 2025
Article

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis.


Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

Related Content

Bridging the Gap:  A Large Pharma Blueprint

Bridging the Gap: A Large Pharma Blueprint

David Kamenir
May 9th 2025
Article

Five steps for organizations in bringing enterprise-level strategies to life.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Sujay Jadhav

How External Control Arms are Improving Clinical Trials: Q&A with Sujay Jadhav

Mike Hollan
May 9th 2025
Article

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy

Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy

Don Tracy, Associate Editor
May 9th 2025
Article

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis.


Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.